Logo image of BSAQ

BLACK SPADE ACQUISITION CO-A (BSAQ) Stock Fundamental Analysis

NYSEARCA:BSAQ - NYSE Arca - KYG115371000 - Common Stock - Currency: USD

10.45  -4.37 (-29.49%)

After market: 11.23 +0.78 (+7.46%)

Fundamental Rating

2

BSAQ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. The financial health of BSAQ is average, but there are quite some concerns on its profitability. BSAQ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BSAQ had positive earnings in the past year.
In the past year BSAQ has reported a negative cash flow from operations.
BSAQ Yearly Net Income VS EBIT VS OCF VS FCFBSAQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 0 10M 20M

1.2 Ratios

Industry RankSector Rank
ROA 3.13%
ROE 3.32%
ROIC 13.41%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSAQ Yearly ROA, ROE, ROICBSAQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 0 5 10

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BSAQ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSAQ Yearly Profit, Operating, Gross MarginsBSAQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BSAQ has about the same amount of shares outstanding.
There is no outstanding debt for BSAQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BSAQ Yearly Shares OutstandingBSAQ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 5M 10M 15M 20M
BSAQ Yearly Total Debt VS Total AssetsBSAQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M

2.2 Solvency

BSAQ has an Altman-Z score of 13.34. This indicates that BSAQ is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for BSAQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.34
ROIC/WACCN/A
WACCN/A
BSAQ Yearly LT Debt VS Equity VS FCFBSAQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.17 indicates that BSAQ may have some problems paying its short term obligations.
BSAQ has a Quick Ratio of 0.17. This is a bad value and indicates that BSAQ is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.17
BSAQ Yearly Current Assets VS Current LiabilitesBSAQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 500K 1M 1.5M 2M 2.5M

More info and screens

1

3. Growth

3.1 Past

BSAQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.82%, which is quite impressive.
EPS 1Y (TTM)33.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BSAQ is valuated quite expensively with a Price/Earnings ratio of 40.19.
When comparing the Price/Earnings ratio of BSAQ to the average of the S&P500 Index (28.79), we can say BSAQ is valued slightly more expensively.
Industry RankSector Rank
PE 40.19
Fwd PE N/A
BSAQ Price Earnings VS Forward Price EarningsBSAQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSAQ Per share dataBSAQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BSAQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLACK SPADE ACQUISITION CO-A

NYSEARCA:BSAQ (8/14/2023, 8:04:01 PM)

After market: 11.23 +0.78 (+7.46%)

10.45

-4.37 (-29.49%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)02-15 2022-02-15
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap220.76M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 40.19
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)0.26
EY2.49%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS7.74
TBVpS7.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.13%
ROE 3.32%
ROCE N/A
ROIC 13.41%
ROICexc 13.43%
ROICexgc 13.43%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.17
Altman-Z 13.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y379.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-165.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.34%
OCF growth 3YN/A
OCF growth 5YN/A